Background. Staphylococcus aureus exhibits varying degrees of reduced vancomycin susceptibility, and strains with intermediate levels of resistance are thought to emerge by antibiotic selection of subpopulations in heterogeneously resistant precursor strains exposed to this antibiotic. We sought to determine the prevalence of and risk factors for carriage of potential heterogeneous vancomycin-intermediate S. aureus (hVISA).
In contrast, the resistance of VISA is thought to be associated with reduced cross-linking and turnover and increased thickness of the bacterial cell wall, limiting the glycopeptide's access to sites of cell wall synthesis [6] . VISA strains are thought to arise by antibiotic selection from a heterogeneously resistant phenotype [7] , although the underlying genetic and biochemical mechanisms are not completely understood [8] . These heteroresistant VISA (hVISA) strains contain subpopulations of vancomycin-resistant cells (MIC, 14 mg/mL) despite having an overall MIC of vancomycin of р4 mg/mL; a recent study described ∼100 such isolates reported in the literature [9] . The term "S. aureus with reduced vancomycin susceptibility" has been put forward to include VRSA, VISA, and those hVISA isolates with MICs of vancomycin of у4 mg/mL [2] .
Identification of hVISA in the laboratory can be dif-ficult [4] , and several methods have been described elsewhere [10, 11] . Hiramatsu et al. [12] proposed a simple screening method, simplified population analysis, in which standard inocula were plated onto brain-heart infusion agar with vancomycin at 4 mg/mL (BHIA-V4) and incubated. Growth at 24 h indicated potential VISA, and growth at 48 h indicated potential hVISA; these phenotypes were confirmed by subculturing onto brain-heart infusion agar with 8 mg/mL vancomycin. This method and those derived from it are among those most commonly used to screen for VISA and hVISA, although positive identification requires further testing [2] . Because antibiotic pressure is thought to promote emergence of VISA and hVISA, these strains or their precursors might be expected to emerge in individuals who have been heavily exposed to vancomycin. Patients with end-stage renal disease treated with hemodialysis may be a sentinel population for such isolates because of high rates of carriage and infection with both methicillinsusceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) [13] [14] [15] , regular contact with the health care system, repeated invasive procedures, and frequent exposure to vancomycin. Moreover, patients undergoing dialysis are frequently given intermittent, single doses of vancomycin, which may lead to levels that are less than the MIC for long intervals. Low, intermittent dosing of some antimicrobials has been associated with the development of resistance [16] [17] [18] . Indeed, renal failure and hemodialysis have been common features among patients from whom VISA and VRSA have been isolated.
To investigate these precursors for hVISA and VISA, we designed a prospective cohort study to estimate the colonization prevalence of potential hVISA strains in hemodialysis patients and to determine whether vancomycin exposure was associated with subsequent acquisition of potential hVISA.
METHODS
Patients who were undergoing long-term hemodialysis were recruited for enrollment from 4 dialysis facilities in the south San Francisco Bay area of California. Subjects who provided written informed consent underwent collection of a nasal swab at enrollment and then quarterly for 2 years. Enrollment began in December 1999 and continued until August 2000; follow-up concluded in August 2002. Surveillance nasal cultures were performed until subjects no longer received hemodialysis at one of these facilities or were lost to follow-up. All procedures were approved by the committees on human research at Satellite Research (Redwood City, CA), the University of California, San Francisco, and each hospital where patients were admitted.
Data collection. Review of medical and pharmacy records for baseline demographic and clinical characteristics was performed at the dialysis center. The variables assessed at enrollment were presence of coronary artery disease (defined as angina, myocardial infarction, or performance of a coronary revascularization procedure), peripheral vascular disease (i.e., amputation, abnormal imaging findings, or performance of a revascularization procedure), cerebrovascular disease (i.e., cerebrovascular accident or transient ischemic attack, abnormal vascular imaging finding, or performance of a revascularization procedure), malignancy (excluding basal cell cancer), diabetes mellitus, and liver disease (i.e., cirrhosis, end-stage liver disease, or hepatitis B core or hepatitis C seropositivity). Use of oral or injected hypoglycemic agents, systemic glucocorticoids, or immunosuppressants within the 6 months preceding enrollment was noted.
Data on vancomycin administration (total grams) and duration of hospitalization (number of hospital days) from the 6 months before enrollment until the end of the follow-up period were recorded from dialysis center and hospital records. These were considered to be exposures only if they occurred before the isolation of potential hVISA from surveillance nasal cultures (for case patients) or until the completion of follow-up (for control patients).
Microbiologic studies. Isolates were identified as S. aureus using standard methods; they were incubated on blood agar plates overnight at 37ЊC, suspended in 10% glycerol, and frozen at Ϫ80ЊC. All S. aureus isolates were tested for b-lactam resistance on Mueller-Hinton agar with 4% sodium chloride and 6 mg/mL oxacillin [19] . Screening for potential heterogeneous vancomycin resistance was adapted from the simplified population analysis method [12] . Using BHIA-V4, 10 6 organisms were deposited as 10 mL of a 0.5 McFarland bacterial suspension; growth was assessed at 24, 48, and 72 h; any growth greater than a pinpoint colony was recorded as a positive result. Standard broth microdilution assays for vancomycin were used to determine MICs [19] . Strains Mu3 (hVISA) and ATCC 29213 (MSSA) were used as controls. We defined potential hVISA as isolates that grew by 72 h on screening media but that had negative confirmatory MIC test results.
Risk factor analysis. Case patients were defined as those from whom potential hVISA were isolated on surveillance nasal cultures. Control patients were defined as patients for whom surveillance cultures did not yield potential hVISA.
Statistical analysis. Prevalences and 95% CIs were calculated using standard equations. Associations with categorical variables were analyzed by Fisher's exact test, and associations with continuous variables were analyzed by Student's t test (for normally distributed variables) or the nonparametric MannWhitney rank sum test. True ORs were determined by logistic regression. Testing was done using 2-sided P values with the Stata statistical software package, version 8.0 (Stata).
RESULTS
A cohort of 211 subjects who were undergoing hemodialysis were identified and followed prospectively for up to 2 years; Downloaded from https://academic.oup.com/cid/article-abstract/40/11/1617/445420 by guest on 11 November 2018 subjects were admitted to 11 area hospitals. The cohort had a slight male predominance, and the mean age was 62 years (table  1) . Most subjects described themselves as white non-Hispanic, Hispanic, or Asian/Pacific Islander. Subjects had received hemodialysis for a median of 23 months, and none were receiving high-flux dialysis. Subjects were distributed equally among 4 sites (data not shown). The most frequent causes for renal failure were diabetes mellitus (49.8%) and hypertension (18.5%).
Other common comorbidities included coronary artery, cerebrovascular, and peripheral vascular diseases. Few subjects had used steroids or other immunosuppressants; only 1 subject had HIV infection, and none used injection drugs.
Complete follow-up data were available for 185 subjects (87.7%); 26 (12.3%) continued to receive hemodialysis but were lost to follow-up, either because they transferred to a different dialysis facility ( ) or because they withdrew from the study n p 23 ( ). Seventy-nine subjects stopped receiving hemodialysis n p 3 during follow-up, because of death ( ), renal transplann p 59 tation ( ), recovery of renal function ( ), or change n p 13 n p 2 to peritoneal dialysis ( ). n p 5 Compliance with quarterly nasal swabs was high: 170 subjects (80.6%) underwent collection of all scheduled swabs, and 33 (15.6%) missed only 1 scheduled nasal swab. Overall, 1357 (96.2%) of 1410 scheduled nasal swabs were performed.
Microbiologic findings. Overall, 376 nasal isolates of S. aureus were obtained from 104 subjects; 107 subjects (50.7%) had no S. aureus nasal isolates detected during the study period. Of the isolates, 297 (80%) were methicillin susceptible and fully vancomycin susceptible, 69 (18.3%) were methicillin resistant and fully vancomycin susceptible, and 10 (2.7%) exhibited potential heterogeneous vancomycin resistance. Of the 10 potential hVISA isolates, 5 were methicillin susceptible and had been obtained from 5 different patients, and 5 were methicillin resistant and had been obtained from 2 patients. No confirmed hVISA or VISA isolates with an MIC of vancomycin of 14 mg/ mL were detected.
The point prevalence of nasal colonization with any S. aureus ranged from 16.2% to 31.3% (mean prevalence, 25.9%) ( figure  1A) . The point prevalence of nasal colonization with vancomycin-susceptible MRSA ranged from 2.0% to 6.8% (mean prevalence, 5.0%); MRSA constituted 10.3%-27.6% (mean prevalence, 19.2%) of S. aureus isolates ( figure 1B) . The point prevalence of nasal colonization with potential hVISA ranged from 0% to 1.4% (mean prevalence, 0.6%); potential hVISA constituted 0%-5.2% (mean prevalence, 2.2%) of S. aureus isolates.
Colonization risk factor analysis. No baseline demographic characteristics or comorbid conditions were associated with isolation of potential hVISA (table 2) . Prior vancomycin exposure and number of days of hospitalization were also not significantly different between patients with and those without subsequent potential hVISA colonization. In a multiple logistic regression model, only an increased number of months of hemodialysis was significant ( ). P p .042 To adjust for possible confounding, in post-hoc analyses, we stratified for presence of diabetes (present in 111 patients, 3 of whom became colonized); no baseline or exposure risk factors were found to predict acquisition of potential hVISA (data not shown). Similarly, when we examined only patients with S. aureus colonization at baseline (58 patients, 5 of whom became colonized), there was no difference in baseline or exposure risk factors among those with and without subsequent colonization with potential hVISA. The power of our study to detect any differences was limited by the small number of isolates identified.
We also performed a subgroup analysis to assess potential risk factors for colonization with the 5 isolates that grew by 48 h (to meet a more rigorous definition of potential hVISA [12] ). Compared with patients who were not colonized, those with potential hVISA colonization (at 48 h) were no more likely to have been exposed to more vancomycin ( ) but were more likely P p .892 to have been undergoing hemodialysis for a greater number of months (
, by the Mann-Whitney rank sum test). P p .011
DISCUSSION
Prevalence. To our knowledge, our study is the first to examine the prevalence of colonization with potential hVISA in a well-defined, at-risk cohort, as well as the first to employ repeated sampling of the same patients. We found that the mean colonization point prevalence was 0.6%; these isolates constituted 2.2% of all S. aureus isolates. Of note, our isolates were found to be potential hVISA on a screening assay; none had an MIC of vancomycin of 14 mg/mL. Thus, the prevalence of confirmed hVISA in this population was 0%, with the upper 95% confidence limit being 1.4%. This is consistent with other studies that have suggested low rates of reduced vancomycin susceptibility in S. aureus. Although those studies used varying definitions and methodologies, most reported hVISA rates of 0%-5% [4, 20] , except for some from parts of continental Europe [21] [22] [23] and Japan [12] .
Early reports suggested that hVISA was limited to MRSA strains. However, MSSA are also exposed to vancomycin (e.g., during empirical therapy for infection, before antibiotic susceptibility results are available, in patients who are allergic to b-lactams, or when less frequent dosing is convenient). Thus, reduced vancomycin susceptibility may not be limited to MRSA strains. We found potential hVISA among MSSA isolates, as well as MRSA. Indeed, since the beginning of our study, there have been other reports of MSSA isolates with reduced susceptibility to vancomycin [7, 24, 25] .
A potential factor in our low observed prevalence of hVISA was the unexpected finding that our hemodialysis patients appeared to be healthier than the patients in other such cohorts. Fewer of our patients were exposed to the presumed relevant risk factors: only 1.4% received vancomycin each month as outpatients (which is one-half of the 2.9% rate reported nationally for patients undergoing long-term hemodialysis [26] ), and only 31% received vancomycin while hospitalized (which is less than the 39% rate reported at one dialysis center [27] ). Moreover, only 6.7% of our patients were admitted to a hospital for any reason in any given month (one-half of the 14% rate reported nationally [26] ). Notwithstanding a potential bias resulting from healthier hemodialysis patients remaining in our study for longer durations, at our baseline survey, only 27% of patients were colonized with S. aureus; this is lower than the rates in previous studies, which have reported a mean colonization rate among hemodialysis patients of 52% (range, 30%-84%) [14] . Of note, nasal decolonization was not implemented in our cohort. Thus, compared with patients in other cohorts, our hemodialysis patients may have been healthier, experienced fewer infections, and had less opportunity for SA-RVS to emerge.
Clinical predictors and outcomes. Most previous surveillance attempts for hVISA have been limited by insufficient patient information, precluding the formal analysis of potential risk factors for carriage of SA-RVS. Those that have allowed comparisons have had conflicting results.
Selection of an appropriate control group is critical to accurately identify particular antibiotics as risk factors for the isolation of resistant organisms without overestimating their magnitude of risk [28] . To ensure that they were selected from the same study base as our case patients, for our control group, we used patients whose surveillance cultures did not yield potential hVISA and who thus remained at risk for infection or colonization with this organism. Use of other control groups (e.g., patients colonized with vancomycin-susceptible S. aureus) may lead to type I errors.
In this study, we only found isolates that were potential hVISA. We did not find that prior vancomycin exposure predicted colonization, whether analyzed as a continuous (table  2) or dichotomous variable (data not shown), nor did we find an association with prior duration of hospitalization. Our ability to find significant associations was limited by the small number of isolates identified. We were unable to test a potential association with end-stage renal disease or dialysis, because we purposely limited our cohort to such patients.
Our finding that vancomycin exposure did not predict isolation of resistant isolates was consistent with the findings of Schwaber et al. [29] , who studied isolates with a similar degree of vancomycin resistance (which they defined as isolates that grew on BHIA-V4 screening media but that lacked subpopulations of cells with an MIC of vancomycin of 14 mg/mL). Likewise, in their study of confirmed hVISA, Charles et al. [30] found no association with vancomycin exposure or previous MRSA infection. On the other hand, our findings were discordant with those of Fridkin et al. [2] , who, in their study of SA-RVS (i.e., confirmed hVISA and VISA) isolates, found that previous vancomycin therapy and prior MRSA infection were associated with SA-RVS. These conflicting results may be because, along the continuum of vancomycin resistance [7] , the isolates in our study and in Schwaber et al. [29] represent a much earlier state in the progression toward increased vancomycin resistance than do the confirmed hVISA and VISA isolates in the study by Fridkin et al. [2] .
One limitation of our study was that only data on vancomycin exposure and the number of hospital-days were recorded prospectively, so we cannot comment on rates of infection, causes of death, or other specific outcomes in patients colonized with potential hVISA. However, given subjects' close contact with their dialysis facilities, we did observe that there was no significant effect on crude mortality: 1 (14.3%) of 7 subjects who were colonized with potential hVISA and 58 (28.4%) of 204 subjects who were not colonized with this organism died during follow-up ( , by Fisher's exact test). Our mor-P p .676 tality results are consistent with those of Schwaber et al. [29] , who found that potential hVISA infection did not affect inhospital mortality rates. On the other hand, studies of confirmed hVISA and VISA infections have had conflicting results: Charles et al. [30] found no difference in 1-month mortality, whereas Fridkin et al. [2] found a 12-fold higher risk of death. Our study examined colonization, and although this may be a precursor to subsequent invasive infection [31, 32] , it is clear that several steps are interposed between nasal carriage with potential hVISA and infection-related death.
A strength of this study was its prospective nature. This allowed exposure data to be collected for our cohort before development of the outcome and allowed us to test the association between multiple potential risk factors and subsequent colonization with potential hVISA. Furthermore, our use of a well-defined cohort is unique among published studies, and it allowed us to measure the true "denominator" of staphylococcal isolates from which our potential hVISA isolates emerged.
Vancomycin susceptibility testing. Multiple investigators have noted technical issues surrounding the definition of hVISA. The proposed reference method for identifying strains of S. aureus with reduced vancomycin susceptibilities is population analysis profiles, although this method is time-consuming and laborious [11] . With this as a gold standard, Walsh et al. [10] found that the simplified population analysis method had a sensitivity of 71% and a specificity of 88%. We adapted the latter method, extending the incubation period to 72 h to increase sensitivity, despite a potential decrease in specificity; 5 of our potential hVISA isolates, which had been isolated from 2 patients, grew only at 72 h. Like previous investigators, we found considerable interoperator variability [10, 33, 34] ; the results reported here were obtained in duplicate, and an appropriate inoculum size was confirmed by quantitative culture. In light of such technical issues, the Centers for Disease Control and Prevention has recommended that multiple methods be used jointly to identify isolates as VISA, although no recommendations have yet been made regarding identification of hVISA.
Summary. In this prospective cohort of hemodialysis patients, we found a low prevalence of potential hVISA and no isolates of confirmed hVISA. Potential hVISA isolates were found among methicillin-susceptible as well as methicillinresistant strains of S. aureus. Potential hVISA colonization was not associated with previous vancomycin exposure (although our ability to detect an association was limited by the small number of cases), so we cannot confirm this as a predictor for hVISA or VISA [25, [35] [36] [37] . There may be an association with increased time receiving dialysis. Given the unclear clinical significance of potential hVISA, it is not clear whether clinical laboratories should identify such strains, or how they should do so.
It is notable that we found no confirmed SA-RVS isolates, because if SA-RVS had been present in our population, we would have been well-situated to identify it: we used a purposely broad definition, a sensitive testing method, and an extended incubation period (despite a potential decrease in specificity) for a cohort of patients who were expected to have been highly exposed to vancomycin. Our ability to identify such isolates may have been limited by the narrow geographic locale of our study, as well as the apparent relative health of our hemodialysis patients. It is unlikely that the low observed prevalence can be explained by the absence of an appropriate S. aureus lineage in our population [38, 39] , because hVISA strains have emerged from all lineages that have produced pandemic MRSA clones [9] . Because we did not find any such isolates, we conclude that the emergence of SA-RVS remains a rare event.
